A type I neurofibromatosis pathogenic mutation gene and an etiological diagnostic reagent based on the mutation gene
A technology for neurofibromatosis and diagnostic reagents, which is applied in the fields of molecular biology and gene detection, and can solve problems such as time-consuming, high detection costs, and high requirements for experimental conditions
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0117] Discovery of NF1 gene mutation in neurofibromatosis type I
[0118] The inventor has carried out gene mutation analysis to 13 routine patients, detailed steps are as follows:
[0119] 1) Detection by mutation analysis reagents: the reagents include 1) total RNA extraction system reagents; 2) RNA reverse transcription and cDNA amplification system reagents; 3) cDNA sequencing system reagents.
[0120] 2) Take 2ml of EDTA anticoagulated peripheral blood samples from suspected patients and normal control samples, extract total RNA, perform reverse transcription PCR, and cDNA amplification to obtain 5 large fragments of cDNA1, 2, 3, 4, and 5 (results see Figure 4 ); Carry out nested PCR to 5 large cDNA fragments, altogether 22 pairs of primers, PCR product agarose electrophoresis result ( Figure 5 ) and sequencing results ( Figure 6 ).
[0121] Type I neurofibromatosis is an autosomal dominant inheritance. In this study, combining the actual situation of the family an...
Embodiment 2
[0135] The usage method and application example of using the kit of the present invention for diagnosis.
[0136] 1. Obtain clinical samples and set up experimental and control groups
[0137] 1) Patient A
[0138] Patient A, a male, had samples from a tertiary hospital. He had 6 café-au-lait spots, axillary or inguinal freckles, and 9 neurofibromas. The initial diagnosis was type 1 neurofibroma.
[0139] 2) Patient B
[0140] Patient B’s sample came from a tertiary hospital. He had 8 or more café-au-lait spots on the skin, freckles in the armpit or groin, and 3 neurofibromas. The initial diagnosis was type 1 neurofibroma.
[0141] 3) Control group
[0142] Three normal subjects were selected as the control group.
[0143] 2. Experimental scheme and steps
[0144] The point mutation analysis kit of the present invention is used for detection: the kit includes 1) total RNA extraction system kit; 2) RNA reverse transcription and cDNA amplification system kit; 3) cDNA sequen...
Embodiment 3
[0180] The foregoing steps are basically the same as in Example 2, except that the detection of patient A and 3 normal persons with no detected mutation: c.7106G>A, p.W2369X continued as follows.
[0181] The NF1 whole gene large fragment deletion analysis kit of the present invention is used for detection, and the kit includes 1) a DNA extraction system kit; 2) an intragenic microsatellite polymorphic marker analysis kit.
[0182] The specific operation is as follows:
[0183] 5. Use the genomic DNA extraction kit to extract the peripheral blood DNA of suspected patient A and normal control (ensure that the extracted DNA storage concentration is >50ng / μl):
[0184] 5.1 Take 300 μl of anticoagulated whole blood, add 600 μl of cell lysate CL to the sample, invert and mix well, centrifuge at 10 000 rpm for 1 min, suck off the supernatant, and leave the cell nucleus pellet.
[0185] 5.2 Repeat the above steps once.
[0186] 5.3 Add 200 μl buffer GS to the cell nucleus pellet co...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com